Wahed Invest’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wahed Invest’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,165	Closed	-$284K	–	220
2025 Q2	$284K	Buy	5,165 +280	+6%	+$16.5K	0.04%	213
2025 Q1	$345K	Buy	4,885 +4	+0.1%	+$269	0.06%	195
2024 Q4	$321K	Buy	4,881 +297	+6%	+$19.9K	0.05%	197
2024 Q3	$322K	Buy	4,584 +470	+11%	+$39.3K	0.06%	194
2024 Q2	$339K	Buy	4,114 +460	+13%	+$38.3K	0.07%	168
2024 Q1	$319K	Buy	3,654 +463	+15%	+$41.4K	0.07%	168
2023 Q4	$308K	Buy	3,191 +290	+10%	+$25.7K	0.09%	160
2023 Q3	$257K	Buy	2,901 +207	+8%	+$18.4K	0.08%	164
2023 Q2	$234K	Buy	2,694 +279	+12%	+$26.3K	0.08%	168
2023 Q1	$235K	Buy	2,415 +62	+3%	+$6.43K	0.1%	153
2022 Q4	$244K	Buy	2,353 +234	+11%	+$22K	0.13%	142
2022 Q3	$180K	Buy	2,119 +146	+7%	+$13K	0.11%	150
2022 Q2	$164K	Buy	+1,973	New	+$157K	0.1%	155
2022 Q1	–	Sell	-2,183	Closed	-$193K	–	176
2021 Q4	$193K	Buy	+2,183	New	+$180K	0.11%	164

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wahed Invest's BMRN Position: Q3 2025 in Review

Wahed Invest sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 5,165 shares — an estimated $284K sold.

Wahed Invest first reported a position in BMRN in Q4 2021 and held it in 14 quarters. The position peaked at $345K in Q1 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Wahed Invest reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Wahed Invest sold 5,165 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $284K.
Wahed Invest first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 14 quarters.
Wahed Invest's BioMarin Pharmaceuticals position peaked at $345K in Q1 2025.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Wahed Invest's 13F filing for Q3 2025, filed 14 Nov 2025.